Macitentan and Tadalafil Combination Therapy in Patients with Pulmonary Arterial Hypertension and Cardiovascular Comorbidities: Real-World Evidence from OPUS and OrPHeUS

By sjmartinez • May 20, 2025

Kim NH, Chin KM, McLaughlin VV, Ong R, MacDonald G, Martin N, Senatore A, Channick R. Macitentan and Tadalafil Combination Therapy in Patients with Pulmonary Arterial Hypertension and Cardiovascular Comorbidities: Real-World Evidence from OPUS and OrPHeUS. Adv Ther. 2025 May 19. doi: 10.1007/s12325-025-03180-0. Epub ahead of print. PMID: 40388087.

Tags: Cardiovascular comorbidities, combination therapy, Hospitalization, Macitentan, Publications, pulmonary arterial hypertension, Pulmonary, Critical Care & Sleep Medicine, real-world data, safety, survival, Tadalafil

A cross-sectional analysis of the association between self-employment, racial and ethnic minority status, sex and cardiovascular disease risk factors among a nationally representative sample

Narain K, Markovic D, Escarce JJ. A cross-sectional analysis of the association between self-employment, racial and ethnic minority status, sex and cardiovascular disease risk factors[...]

Single-cell analyses identify monocyte gene expression profiles that influence HIV-1 reservoir size in acutely treated cohorts

Ehrenberg PK, Geretz A, Volcic M, Izumi T, Yum LK, Waickman A, Shangguan S, Paquin-Proulx D, Creegan M, Bose M, Machmach K, McGraw A, Narahari[...]

Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial

Hu X, Curigliano G, Yonemori K, Bardia A, Barrios CH, Sohn J, Lévy C, Jacot W, Tsurutani J, Roborel de Climens A, Wu X, Andrzejuk-Ćwik[...]